Endologix, Inc.  

(Public, NASDAQ:ELGX)   Watch this stock  
Find more results for Gregory Guido�
14.82
+0.21 (1.44%)
Real-time:   1:13PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.41 - 14.93
52 week 10.29 - 17.98
Open 14.66
Vol / Avg. 485,025.00/574,902.00
Mkt cap 976.07M
P/E     -
Div/yield     -
EPS -0.33
Shares 66.99M
Beta 1.08
Inst. own 98%
Feb 25, 2015
Q4 2014 Endologix Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
Endologix Inc at Oppenheimer Healthcare Conference
Dec 2, 2014
Endologix Inc at Piper Jaffray Healthcare Conference
Nov 20, 2014
Endologix Inc Investor Meeting
Nov 20, 2014
Endologix Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 18, 2014
Endologix Inc at Stifel Healthcare Conference
Nov 11, 2014
Endologix Inc at Stephens Fall Investment Conference
Oct 30, 2014
Q3 2014 Endologix Inc Earnings Call - Webcast
Oct 30, 2014
Q3 2014 Endologix Inc Earnings Release
Sep 29, 2014
Preliminary Q3 2014 Endologix Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -37.52% -12.15%
Operating margin -23.49% -14.27%
EBITD margin - -6.02%
Return on average assets -21.51% -7.63%
Return on average equity -40.13% -16.14%
Employees 482 -
CDP Score - -

Address

2 Musick
IRVINE, CA 92618-1631
United States - Map
+1-949-5957200 (Phone)
+1-949-4579561 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Endologix, Inc. (Endologix) is engaged in developing, manufacturing, marketing, and selling medical devices for the treatment of aortic disorders. Endologix products are intended for the treatment of abdominal aortic aneurysms (AAA). The Company�s AAA products are built on one of two platforms: minimally-invasive endovascular repair (EVAR) or endovascular sealing (EVAS), Endologix�s solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR portfolio includes products, such as Endologix AFX Endovascular AAA System (AFX), VELA Proximal Endograft (VELA) and Endologix Intuitrak Endovascular AAA System (Intuitrak). The EVAS product is the Nellix Endovascular Aneurysm Sealing System (Nellix EVAS System).

Officers and directors

John McDermott Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Robert D. Mitchell President
Age: 52
Bio & Compensation  - Reuters
Shelley B. Thunen Chief Financial Officer and Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
Todd G. Abraham Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Joseph A. DeJohn Vice President - Sales
Age: 53
Bio & Compensation  - Reuters
David M. Jennings Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Jose A. Lima Vice President - Quality
Age: 48
Bio & Compensation  - Reuters
Charles Love Vice President - Clinical Affairs
Age: 52
Bio & Compensation  - Reuters
James E. Machek Vice President - Research and Development
Age: 56
Bio & Compensation  - Reuters
Janet Fauls Director - Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters